Search

everythinglearnresearchcommunity

for

Search:↓

The user stopped taking finasteride due to erectile dysfunction, which they later realized was caused by excessive porn use and not the medication. They resumed finasteride, added dutasteride, and are using minoxidil and microneedling to regain hair.

A 23-year-old male taking 0.25 mg finasteride for 40 days noticed reduced hair shedding and improved hair texture but experienced watery semen, which might be temporary. Overejaculation and finasteride can cause this, and it usually resolves, but consulting a healthcare provider is advised if it persists.

A 25-year-old man had a 3500 graft hair transplant on the frontal region and is happy with the results after 8 months. He has been on minoxidil and finasteride, switched to dutasteride, added ketoconazole shampoo for seborrheic dermatitis, and is considering a second transplant for the mid scalp/crown.

The user has been using finasteride and topical minoxidil for 8.5 months, with initial progress slowed due to stopping microneedling. They plan to resume microneedling and consider a hair transplant in the future.

Stem-cell hair transplants could potentially create thousands of grafts from a single donor graft, offering a solution for hair loss with DHT-resistant hair. Companies like Stemson Therapeutics and OrganTech are working on this technology, which may become available in the future, possibly reducing the cost and making it widely accessible.

A 29-year-old male experienced hair regrowth using minoxidil 5% foam and KX826 after stopping finasteride due to side effects. He applies both treatments once daily and reports no side effects from the current regimen.

A user shared their 21-month hair regrowth journey using oral Finasteride 1mg daily and Minoxidil 5% topical applications. Despite initial discouragement due to slow progress, they saw significant improvement, reducing the need for a hair transplant to minor fill-ins at the front hairline.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Temporal peaks are crucial for a natural-looking hair transplant, but they are challenging to achieve due to the need for precise angles and appropriate hair thickness. Many users emphasize the importance of finding a skilled surgeon and using finasteride to maintain hairline stability.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.